Revolution Medicines (RVMD) Stock News, Feb-Jun 2025

Revolution Medicines (NASDAQ: RVMD) has received FDA Breakthrough Therapy Designation for daraxonrasib, targeting previously treated metastatic pancreatic cancer with KRAS G12 mutations. The designation is based on promising Phase 1 trial data and aims to expedite development and review of this potential treatment. The company is currently conducting RASolute 302, a Phase 3 registrational study expected to complete enrollment in 2025, with results anticipated in 2026. The study focuses on patients with pancreatic ductal adenocarcinoma (PDAC), where over 90% of cases carry RAS mutations, with approximately 85% specifically having KRAS G12 mutations. The trial's dual primary endpoints include progression-free survival and overall survival in the core patient population.

Revolution Medicines (RVMD) has initiated dosing in RASolve 301, a global Phase 3 clinical trial evaluating daraxonrasib against docetaxel chemotherapy in previously treated RAS mutant non-small cell lung cancer (NSCLC) patients. The trial will enroll approximately 420 patients who have received 1-2 prior therapies. The study focuses on patients with NSCLC carrying RAS mutations at position G12 (core population) and other specific RAS mutations (expanded population). Daraxonrasib targets RAS mutations present in 30% of NSCLC cases. The trial's dual primary endpoints are progression-free survival and overall survival in the core population. The decision to proceed with Phase 3 was based on promising early evidence from a single-arm trial showing acceptable safety and encouraging antitumor activity.

Revolution Medicines (RVMD) reported Q1 2025 financial results and clinical progress. The company reported a net loss of $213.4M, up from $116M in Q1 2024, with $2.1B in cash expected to fund operations into 2H 2027. Key clinical highlights include strong enrollment in Phase 3 trials for daraxonrasib, particularly RASolute 302 for pancreatic cancer. The company shared promising data for its RAS(ON) inhibitors: zoldonrasib showed 61% ORR in NSCLC, elironrasib demonstrated 56% ORR with 9.9 months median PFS, and various combination therapies displayed encouraging results. Notable combinations include daraxonrasib with pembrolizumab achieving 86% ORR in first-line NSCLC. The company strengthened its commercial capabilities by appointing Anthony Mancini as chief global commercialization officer.

Revolution Medicines (Nasdaq: RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, has scheduled its Q1 2025 financial results announcement for May 7, 2025, after market close.

The company's senior management team will host a webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss:

• First quarter 2025 financial performance
• Updates on corporate progress

Investors and interested parties can access the live webcast through the company's investor relations website at ir.revmed.com/events-and-presentations. A replay of the webcast will remain available on the website for at least 14 days following the live presentation.

Revolution Medicines (RVMD) has presented initial clinical data for zoldonrasib (RMC-9805), their RAS(ON) G12D-selective inhibitor, in treating KRAS G12D mutant non-small cell lung cancer (NSCLC) patients. The Phase 1 study results were presented at the 2025 AACR Annual Meeting.

Key findings from the study with 90 solid tumor patients treated with 1200 mg once daily dose showed:

• 61% objective response rate in 18 efficacy-evaluable NSCLC patients
• 89% disease control rate
• 98% mean dose intensity with no dose limiting toxicities
• Acceptable safety profile with mostly Grade 1 or 2 adverse events

Common treatment-related adverse events included nausea (39%), diarrhea (24%), vomiting (18%), and rash (12%). Only 2% of patients experienced Grade 3 events, which resolved after dose interruption.

Revolution Medicines (RVMD) announced 11 presentations at the upcoming 2025 AACR Annual Meeting in Chicago (April 25-30, 2025). The highlight will be the first clinical data presentation of zoldonrasib, their RAS(ON) G12D-selective inhibitor, in non-small cell lung cancer patients during a late-breaking oral session.

Key presentations include preliminary safety and antitumor activity data of zoldonrasib in KRAS G12D NSCLC patients, the discovery of RMC-5127 (a RAS(ON) G12V-selective inhibitor), and clinical activity data of daraxonrasib in RAS mutant NSCLC. Additional presentations will cover resistance mechanisms, combination therapies, and immune response in various cancer types including pancreatic and colorectal cancers.

Revolution Medicines (RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its participation in two major investor conferences in April 2025.

The company's CEO and chairman, Mark A. Goldsmith, M.D., Ph.D., will engage in fireside chats at the following events:

• Needham 24th Annual Virtual Healthcare Conference on Monday, April 7 at 2:15 p.m. ET
• Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9 at 1:00 p.m. ET

Live webcasts and replays of both events will be accessible through the company's investor relations website for a minimum of 14 days following the presentations.

Revolution Medicines (RVMD) reported its Q4 and full year 2024 financial results, highlighting progress in its RAS-focused cancer drug development programs. The company ended Q4 2024 with a net loss of $194.6M, compared to $161.5M in Q4 2023, while full-year 2024 net loss was $600.1M.

Key developments include advancing Phase 3 trials for daraxonrasib in pancreatic and lung cancers. The company expects to complete enrollment in the RASolute 302 trial for metastatic pancreatic cancer in 2025, with data readout in 2026. Two additional registrational trials for pancreatic cancer are planned for H2 2025.

Financially, RVMD strengthened its position through an $823M public equity offering in December 2024, ending the year with $2.3B in cash. The company projects 2025 GAAP net loss between $840M-$900M and expects current funds to support operations into H2 2027.

Revolution Medicines (Nasdaq: RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its participation in three major investor conferences in March 2025.

The company's CEO and chairman, Mark A. Goldsmith, M.D., Ph.D., will participate in fireside chats at:

• TD Cowen 45th Annual Healthcare Conference on March 3 at 1:50 p.m. ET
• Barclays 27th Annual Global Healthcare Conference on March 11 at 8:00 a.m. ET
• 2025 Leerink Partners Global Healthcare Conference on March 12 at 2:20 p.m. ET

Live webcasts of these events will be available on the company's investor relations website, with replays accessible for at least 14 days following the presentations.